Research dossier
Clinical research on Resveratrol
8 trials reviewed across 4 indications.
Strongest evidence
Blood sugar & insulin sensitivity
Mechanism
Proposed activation of SIRT1 and AMPK pathways improving mitochondrial function and insulin signaling — strongly demonstrated in rodents, weakly in humans.
Meta-analysis shows modest glycemic improvement, but ONLY in people who already have diabetes. In metabolically healthy adults (Yoshino 2012, clamp), there was no effect at all. Real but narrow.
Benefit confined to diabetics. No glycemic effect in healthy or non-obese adults.
Trials cited
Resveratrol and glycemic control (meta-analysis of 11 RCTs)
mixed · Meta-analysis
Liu et al., 2014, American Journal of Clinical Nutritionn=388Pooling 11 trials (388 subjects), resveratrol significantly improved fasting glucose, insulin, HbA1c, and insulin resistance — but ONLY in people with diabetes. In non-diabetic participants there was no significant glycemic effect.
Benefit confined to diabetics; null in healthy adults. Small total sample and heterogeneous dosing.
Resveratrol as a calorie-restriction mimetic in obese men
positive · RCT
Timmers et al., 2011, Cell Metabolismn=11Industry-fundedThe flagship 'calorie-restriction mimetic' trial: 11 obese men showed reduced sleeping metabolic rate, AMPK/SIRT1 activation in muscle, lower glucose, triglycerides, and systolic BP after 30 days. The single most-cited human resveratrol study — and it has only 11 participants.
n=11. Tiny, short, and industry-supplied (resVida from DSM). A widely extrapolated proof-of-concept, not a robust outcome trial.
Resveratrol in non-obese postmenopausal women (null)
Null · RCT
Yoshino et al., 2012, Cell Metabolismn=29A rigorous clamp study found resveratrol raised plasma levels but did NOT improve insulin sensitivity, body composition, resting metabolic rate, lipids, or inflammation. The direct counterpoint to Timmers — in metabolically healthy people, nothing happened.
Methodologically stronger than many positive trials (hyperinsulinemic-euglycemic clamp). A clear null in a non-diseased population.
Cardiovascular & blood pressure
Mechanism
Proposed endothelial nitric-oxide and antioxidant effects underpin the 'red wine / French paradox' story.
A high-dose subgroup showed a systolic BP drop, but with a wide, fragile confidence interval. Meanwhile resveratrol BLUNTED exercise-induced cardiovascular gains (Gliemann 2013), and dietary intake showed no mortality or CVD benefit in a 9-year cohort (Semba 2014). The cardio story is far weaker than marketing implies.
Possible BP effect only at ≥150 mg/day. May interfere with exercise adaptations — a real concern for active adults.
Resveratrol and blood pressure (meta-analysis of 6 RCTs)
mixed · Meta-analysis
Liu et al., 2015, Clinical Nutritionn=247Pooled trials found no overall BP effect, but a high-dose subgroup (≥150 mg/day) showed a large systolic drop (~−11.9 mmHg). The wide confidence interval and small subgroup mean this should be read cautiously, not as an established effect.
The headline systolic effect rests on a small high-dose subgroup with a very wide confidence interval (−21 to −3 mmHg). Fragile.
Resveratrol blunts exercise benefits in aged men (negative)
negative · RCT
Gliemann et al., 2013, The Journal of Physiologyn=27Aged men did high-intensity exercise training with resveratrol or placebo. Exercise improved blood pressure, VO2max, LDL, and vascular function in the placebo group — but resveratrol BLUNTED several of these gains. An actively harmful interaction with one of the most evidence-based health interventions there is.
Small but well-controlled. A genuinely negative result: resveratrol interfered with the cardiovascular adaptations to exercise.
Dietary resveratrol and mortality (InCHIANTI, null)
Null · Observational
Semba et al., 2014, JAMA Internal Medicinen=783In ~783 older Italian adults followed 9 years, urinary resveratrol metabolites were NOT associated with longevity, heart disease, cancer, or inflammation. The 'red wine resveratrol explains the French paradox' story does not survive a real population cohort.
Observational and dietary (not supplemental) intake, but directly undercuts the longevity-from-resveratrol narrative at population scale.
Cognition (postmenopausal)
Mechanism
Proposed improvement in cerebrovascular responsiveness — increasing blood-flow response to cognitive demand.
The RESHAW trials report improved cognition and cerebrovascular responsiveness in postmenopausal women over 12+ months. The most encouraging long-term human signal — but it is industry-funded, from a single group, and unreplicated.
Signal is specific to postmenopausal women and industry-funded. Do not generalize to other populations or claim proven cognitive benefit.
RESHAW — resveratrol for cognition in postmenopausal women
positive · RCT
Thaung Zaw et al., 2020, Nutrientsn=129Industry-fundedA 12-month phase of the RESHAW crossover study reported improved overall cognitive performance and cerebrovascular responsiveness in postmenopausal women. The strongest long-duration human cognitive signal for resveratrol — but in one specific population and industry-funded.
Industry-funded (Evolva supplied test material and supplementary funding). Single research group; cognitive composites are sensitive to multiple-comparison and crossover effects. Not yet independently replicated.
Longevity & cellular aging
Mechanism
SIRT1 ('sirtuin') activation extended lifespan in yeast, worms, flies, and obese mice. Whether oral resveratrol meaningfully activates SIRT1 in humans is disputed.
This is the headline claim and the weakest one. No human trial shows resveratrol extends lifespan or healthspan. The InCHIANTI cohort found no link between resveratrol intake and longevity. The famous SIRT1/sirtuin lifespan data are from yeast, worms, flies, and rodents.
No human longevity evidence exists. Animal lifespan findings have not translated.
Resveratrol as a calorie-restriction mimetic in obese men
positive · RCT
Timmers et al., 2011, Cell Metabolismn=11Industry-fundedThe flagship 'calorie-restriction mimetic' trial: 11 obese men showed reduced sleeping metabolic rate, AMPK/SIRT1 activation in muscle, lower glucose, triglycerides, and systolic BP after 30 days. The single most-cited human resveratrol study — and it has only 11 participants.
n=11. Tiny, short, and industry-supplied (resVida from DSM). A widely extrapolated proof-of-concept, not a robust outcome trial.
Dietary resveratrol and mortality (InCHIANTI, null)
Null · Observational
Semba et al., 2014, JAMA Internal Medicinen=783In ~783 older Italian adults followed 9 years, urinary resveratrol metabolites were NOT associated with longevity, heart disease, cancer, or inflammation. The 'red wine resveratrol explains the French paradox' story does not survive a real population cohort.
Observational and dietary (not supplemental) intake, but directly undercuts the longevity-from-resveratrol narrative at population scale.
3 forms of Resveratrol compared
Trans-resveratrol
Poor — under ~1% reaches plasma unchanged; rapidly glucuronidated and sulfated
Best forThe bioactive isomer used in essentially every clinical trialTrans- is the active configuration (cis- is largely inert). Even so, oral absorption is so low that researchers debate whether plasma levels ever reach the concentrations that drive in-vitro effects.
Resveratrol (unspecified)
Poor; quality depends on trans- content and source
Best forGeneral supplementMost commercial resveratrol is sourced from Japanese knotweed (Polygonum cuspidatum). Look for standardized trans-resveratrol content — total 'resveratrol' on a label can include the inactive cis- form and emodin co-extractives.
Japanese knotweed extract
Variable; depends on standardization
Best forThe dominant commercial source of resveratrolCheaper than grape-derived resveratrol but co-extracts emodin (a laxative anthraquinone), which can contribute to GI side effects.
Side effects and drug interactions
Side effects
Diarrhea and GI distress
Common · Mild-to-moderate at 2.5 g/day and above (Brown 2010)
The dose-limiting side effect. High doses needed to overcome poor absorption are exactly the doses that irritate the gut.
Worse with:japanese knotweed
Nausea and abdominal discomfort
Uncommon · Higher gram-level doses
Reported at higher doses, often alongside loose stools.
Blunting of exercise adaptations
Uncommon · 250 mg/day in the Gliemann trial
In aged men, resveratrol reduced several cardiovascular benefits of exercise training versus placebo.
Estrogenic activity
Rare
Resveratrol is a phytoestrogen and can act on estrogen receptors. Theoretical concern in hormone-sensitive conditions.
Drug interactions
Other
CYP3A4 substratesCYP2C9 substrateswarfarinResveratrol can inhibit CYP3A4, CYP2C9, and other CYP enzymes in vitro, potentially raising levels of drugs cleared by these pathways.
Caution with narrow-therapeutic-index drugs (e.g. warfarin). Clinical significance at supplemental doses is not well characterized — discuss with a prescriber.
Additive effect
anticoagulantsantiplatelet drugsNSAIDsResveratrol has mild antiplatelet activity that may be additive with blood-thinning agents.
Watch for additive bleeding risk; relevant before surgery.
Other
estrogen-sensitive therapiestamoxifenAs a phytoestrogen, resveratrol may interact with estrogenic or anti-estrogenic therapies.
Avoid high-dose supplementation in hormone-sensitive cancers without oncology guidance.
Other critical caveats
- Resveratrol research was tainted by one of science's largest fraud cases: in 2012 the University of Connecticut found cardiovascular researcher Dipak K. Das responsible for 145 counts of data fabrication/falsification across years of resveratrol work, leading to around 20 journal retractions. This does not invalidate all resveratrol science, but it means a chunk of the early cardioprotection literature is untrustworthy — read the field with extra skepticism.
- The famous longevity and SIRT1 'sirtuin' claims come from yeast, worms, flies, and obese mice. No human trial has shown resveratrol extends lifespan or healthspan, and a 9-year cohort (InCHIANTI) found no link between intake and mortality.
- Oral bioavailability is the central problem: under ~1% of an oral dose reaches the bloodstream as intact resveratrol. The in-vitro concentrations behind most mechanistic claims are likely never achieved in human tissue at safe doses.
- One well-controlled trial found resveratrol BLUNTED the cardiovascular benefits of exercise training in older men. If you exercise, this is a reason for caution, not enthusiasm.
- The doses high enough to plausibly do something (grams per day) are the doses that cause diarrhea and GI distress.
Frequently asked
Does resveratrol actually extend lifespan or slow aging in humans?
No human study shows this. The longevity claims come from yeast, worms, flies, and obese mice via SIRT1 activation. In people, a 9-year cohort of older adults found no association between resveratrol intake and longevity, heart disease, or cancer. Treat 'anti-aging resveratrol' as an unproven hypothesis, not an established benefit.Why do supplements need such high resveratrol doses?
Because oral bioavailability is terrible — under about 1% reaches your bloodstream intact, as it's rapidly metabolized in the gut and liver. That's why trials use hundreds of milligrams to grams. The catch: doses of 2.5 g/day and up commonly cause diarrhea and GI discomfort.Wasn't there a resveratrol research scandal?
Yes. In 2012, the University of Connecticut found cardiovascular researcher Dipak K. Das responsible for 145 counts of data fabrication or falsification, triggering around 20 retractions. It doesn't erase all resveratrol science, but it badly damaged the early cardioprotection literature — a real reason to be skeptical of older positive findings.Will resveratrol help my heart or blood pressure?
Weakly, at best. A high-dose subgroup in one meta-analysis showed a blood-pressure drop, but with a fragile, wide confidence interval. More concerning: a controlled trial found resveratrol reduced the cardiovascular benefits of exercise in older men. The overall cardio case is much weaker than the marketing suggests.Is there anything resveratrol is genuinely useful for?
The least-weak signals are modest glucose improvement in people who already have diabetes, and a cognition signal in postmenopausal women from the (industry-funded) RESHAW trials. Both are limited and unreplicated by independent groups. For healthy people, the human evidence is largely null.
References
- 01Examine.com — Resveratrol
- 02Liu et al., 2014 — Resveratrol and glycemic control meta-analysis (Am J Clin Nutr)
- 03Yoshino et al., 2012 — Null metabolic RCT (Cell Metabolism)
- 04Semba et al., 2014 — Resveratrol and mortality, InCHIANTI cohort (JAMA Intern Med)
- 05Gliemann et al., 2013 — Resveratrol blunts exercise benefits (J Physiol)
- 06Dipak K. Das research-misconduct case (Retraction Watch overview)
Last reviewed2026-05-24